Adherence and persistence are key considerations in patient-centric treatment selection for T2D management. The objective of this retrospective real-world study was to assess 1-year adherence and persistence using different measures among injection naïve patients with T2D initiating DU vs. BI. A U.S. claims database was used to identify patients with T2D initiating DU or BI between Nov’14 - Apr’17 (index date=earliest fill date). Patients ≥18 years, with no claim for any antidiabetic injectable in the 6 months pre-index period (baseline), continuous enrollment and ≥1 HbA1c result at baseline and 1-year post-index were included. Two widely used measures for assessing persistence of injectables in the real-world were implemented. DU users were propensity-matched 1:1 to BI users. Matched cohorts (903 pairs) were balanced in baseline patient characteristics with mean age of 54 years. Key study outcomes are included in the Table. Using the 45-day gap measure, more BI vs. DU patients discontinued their therapy but more BI patients restarted their index therapy. More DU vs. BI patients discontinued based on the 90th percentile measure, and more DU patients restarted their index therapy. In this real-world study, DU demonstrated higher adherence than BI. Given the results, the most appropriate persistence measure may vary for different classes of antidiabetic injectables.
R. Mody: Employee; Self; Eli Lilly and Company. Q. Huang: None. M. Yu: Employee; Self; Eli Lilly and Company. Employee; Spouse/Partner; Lifelabs. Stock/Shareholder; Self; Eli Lilly and Company. L. Wang: Employee; Self; HealthCore. Employee; Spouse/Partner; Janssen Pharmaceuticals, Inc. X. Zhang: None. M. Grabner: None. H. Patel: Employee; Self; Eli Lilly and Company. Stock/Shareholder; Self; Eli Lilly and Company.
Eli Lilly and Company